FiBreath

Company Overview

Snapshot

Founded in July 2025 by Hai Zaguri and Ron Bessler, FiBreath operates with 1–10 employees. The company has raised $9K across one funding round and secured a grant from BizTEC in July 2025.

Business overview

FiBreath is a Health Tech & Life Sciences company focused on addressing respiratory diseases, particularly asthma and COPD. The company is developing a novel inhaled-therapy platform designed for deep-lung delivery to enhance patient outcomes. Its business model centers on licensing this platform to pharmaceutical and inhaler manufacturers, generating revenue through royalties. FiBreath operates within the Pharma & Medical Biotechnology sector, specifically in Drug Delivery, targeting the Healthcare & Life Sciences market globally, including the Americas, Asia, and Europe.

Company Intelligence Q&A

When was FiBreath founded and by whom?

FiBreath was founded in July 2025 by Hai Zaguri, who serves as CEO, and Ron Bessler, the CTO.

What is FiBreath's primary focus?

FiBreath is focused on redefining inhalation therapy to address the global burden of respiratory diseases like asthma and COPD, aiming to empower patients with enhanced deep-lung delivery solutions.

What is FiBreath's business model?

FiBreath's business model involves licensing its novel inhaled-therapy platform to leading pharmaceutical and inhaler manufacturers in exchange for royalties.

What is FiBreath's current product development stage?

FiBreath is currently in the R&D stage, operating in stealth mode to develop its next-gen inhaler platform.

Which markets does FiBreath target?

FiBreath targets global markets, including the Americas (North and South America), Central America, Asia, and Europe, for its inhalation therapy solutions.